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Abstract: Nowadays, it is known that oxidative stress plays at least two roles within the cell,
the generation of cellular damage and the involvement in several signaling pathways in its balanced
normal state. So far, a substantial amount of time and effort has been expended in the search for a
clear link between cardiovascular disease (CVD) and the effects of oxidative stress. Here, we present
an overview of the different sources and types of reactive oxygen species in CVD, highlight the
relationship between CVD and oxidative stress and discuss the most prominent molecules that play
an important role in CVD pathophysiology. Details are given regarding common pharmacological
treatments used for cardiovascular distress and how some of them are acting upon ROS-related
pathways and molecules. Novel therapies, recently proposed ROS biomarkers, as well as future
challenges in the field are addressed. It is apparent that the search for a better understanding of how
ROS are contributing to the pathophysiology of CVD is far from over, and new approaches and more
suitable biomarkers are needed for the latter to be accomplished.
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1. Introduction
In 1985, the term oxidative stress was coined by Sies [1] to broadly describe a disturbance in the
balance of reactive oxygen species (ROS) and antioxidants. However, its definition has been changing
over the years due to the wide variety of outcomes it can produce. Currently, oxidative stress is
defined as an event where a transient or permanent perturbation in the ROS balance-state generates
physiological consequences within the cell, for which the precise outcome depends on ROS targets
and concentrations.
Besides cellular damage, ROS have also been shown to be involved as messengers in signaling
pathways in a balanced-“normal”-state. In a homeostatic living system, ROS concentrations fluctuate
in a controlled manner and are preserved through antioxidants and other enzymes [2]. Once this
homeostatic state starts to fail and ROS levels cannot be controlled, oxidative stress becomes apparent.
Guanylate cyclase activation, nervous system physiology regulation, immune cell differentiation and
response regulation [3–6], as well as the mediation of phosphatases, kinases, growth factor signaling
pathways and even stem cell differentiation [7–9] are some of the mechanisms that have been reported
to be influenced by ROS, producing either beneficial or damaging consequences.
Xenobiotics, such as radiation, drugs, habits like smoking, as well as environmental agents,
interact with cellular sources of ROS, inducing its generation. Mitochondria, endoplasmic reticulum,
peroxisomes and enzyme systems, involving for example NADP oxidases and xanthine oxidase,
are some of the intracellular ROS sources. Additionally, ROS action varies according to different cell
types and depending on its source, type, location, concentration and target, thereby leading to a variety
of physiological or pathological consequences [10,11]. Moreover, there are different types of ROS,
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such as superoxide (−O2), hydroxyl radicals (HO), hydrogen peroxide (H2O2), singlet oxygen (O2),
peroxynitrite (OONO−) and nitric oxide (NO) [11]. Overwhelming quantities of ROS are involved
in several pathologies, such as cancer, neurodegenerative diseases, diabetes and cardiovascular
diseases (CVD), due to its role promoting inflammation, damaging DNA and proteins, as well as lipid
peroxidation [12]. In this review, the main focus will be CVD and the influence that oxidative stress
has on these pathologies.
2. CVD Highlights and Their Relationship with Oxidative Stress
CVD are multifactorial disorders and, according to the World Health Organization (WHO),
are the leading causes of death worldwide [13]. CVD represents 31% of deaths globally in 2013,
causing approximately 17.5 million deaths per year. The 2016 CVD statistics update by the American
Heart Association (AHA) reported that about one in three persons in the U.S. was affected with
one or more CVD types in 2013 [14], which has also an economic impact. Globally, its costs are
constantly rising, with an estimate in 2010 of $863 billion and an expectation of $1044 billion by 2030.
The basis of CVD encompasses damage and remodelling of blood vessels that can result in blood
flow restrictions affecting the heart and nervous system. There are several disorders that comprise
CVD, namely coronary artery disease (CAD), stroke, hypertension, heart failure, rheumatic aetiologies,
congenital heart disease and peripheral vascular disease. In 2011, the AHA included preeclampsia
(PE) as a risk factor of CVD. Within the CVD spectrum, other well-known risk factors, such as obesity,
diabetes, tobacco smoking, a sedentary and unhealthy lifestyle, family history, genetic predisposition
and oxidative stress, also play an important role in CVD. Aging is another risk factor, though a
non-modifiable one, since it increases CVD prevalence mainly due to the accumulation of oxidative
damage [15].
The main leading cause of CVD is atherosclerosis. It is the hardening and narrowing of arteries
that consequently reduces the flow and delivery of blood and oxygen throughout the body. It is
characterized by plaque formation in the inner coronary artery walls, consisting of bulks of LDL
cholesterol, cellular waste and surrounding materials [16]. Atherosclerotic plaques are caused by
molecular changes induced by cytokines, hormones, growth factors and oxidative species, mainly due
to the interaction between endothelial cells, LDLs and macrophages. Endocytosis of oxidized LDLs
occurs within macrophages, an event that is quite slow and, therefore, can lead to an accumulation in
the intima resulting in the development of atherosclerosis [17].
LDLs can be chemically modified in several different ways. Native LDL molecules are susceptible
to be oxidized (oxLDL) [18], glycated (gLDL) [19], acetylated (acLDL) [20], ethylated [21] and
methylated [21]. Studies regarding endothelial cell injury caused by modification on LDLs have pointed
to an association of gLDL and oxLDL with the initiation of atherogenic processes [22]. Nowadays, it is
clear that changes in LDL and its components play an important role in the initiation and generation of
atherogenic effects, especially when these modifications occur within cells of the arterial wall. Modified
components of native LDLs, such as apoB (LDL surface protein), which mediates the ability of LDL to
bind to its receptor, have been the subject of studies in order to elucidate the relationship of these types
of modification and the triggering of the atherogenic processes [23].
A non-enzymatic reaction oversees the glycation of lipoproteins in arterial walls. The extent of this
modification is dependent on the glucose concentrations and the exposure time of native non-modified
LDLs [24]. Non-enzymatic glycation of LDLs can occur in all patients, but subjects with diabetes
mellitus can present more severe effects. Glycation of LDL mainly occurs in lysine residues of apoB
that are located in an LDL receptor-binding domain. This change causes the loss of electropositive
charges on the modified LDL, decreasing its affinity to its receptor, thus increasing its lifetime in
plasma [25]. All of this was shown to enhance the uptake of gLDLs by human aortic cells [26] and
macrophages [27], promoting the accumulation of cholesteryl esters and atherosclerosis. An additional
atherogenic effect of LDL glycation is that the modified molecules become more susceptible to be
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oxidized, creating a double modified native LDL (gly/oxLDL), which might have a greater atherogenic
potential in comparison with gLDL [28].
In early stages of atherogenesis, LDLs are oxidized (oxLDL). Once oxLDLs starts to accumulate,
the disease progresses. oxLDL activates the endothelium by the production of adhesion molecules,
which recruit monocytes and T-cells, considered a key stimulator for the immune system response [17].
Once adhesion of inflammatory cells to endothelial cells takes place, migration into the arterial intima
follows. Here, monocytes differentiate into macrophages that induce atherosclerosis progression by
promoting internalization of oxLDL and, along with T-cells, release pro-inflammatory cytokines and
ROS to keep oxidizing LDLs [29]. This leads to smooth-muscle cell migration into the intima, followed
by proliferation. This contributes to the formation of an atherosclerotic plaque by apoptosis or foam
cell formation [30]. Atherosclerosis progresses and CVD genesis starts by accumulation and conversion
of these molecules into potentially damaging forms, (Figure 1). As mentioned above, damaging
ROS species have shown a strong association with the vascular endothelium. The ROS influence on
endothelial underlying molecules that can promote apoptosis, necrosis and therefore thrombosis of
atherosclerotic plaques makes oxidative stress a crucial hallmark of CVD and is defined as its early
causative factor [31,32].
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Figure 1. Atherosclerotic plaque formation process. LDLs at a high concentration inhibit endothelial 
cells’ (EC) endocytosis capacity, migrate and accumulate in the intima. LDLs get oxidized and induce 
VCAM  (green  square)  expression  in  EC.  Monocytes  are  recruited  into  the  intima  by  VCAM 
interaction. Monocytes  transform  into macrophages, which  take‐up  oxLDLs,  forming  foam  cells. 
Macrophages  and  EC  secrete  chemokines  and  recruit  T‐cells.  T‐cells  produce  TNF‐alpha  and 
IFN‐gamma, amplifying inflammation. Fibroblast growth factor (FGF) and platelet‐derived growth 
factor  (PDGF)  stimulate  smooth‐muscle  cells  (SMC) migration  and  proliferation.  SMCs  can  also 
accumulate  lipids,  migrate  and  proliferate.  A  lipid  core  is  generated  with  necrotic  foam  cells 
surrounded by SMCs and a collagen fibrous cap, resulting in thrombus formation. 
3. ROS Types and Principal Sources in CVD 
Among the ROS that have been associated with CVD induction or progression are  −O2, H2O2, 
OONO−  and HO.  −O2  and H2O2  are  ROS  produced  enzymatically  and  have  been  shown  to  be 
involved  in  physiological  signaling  and  pathologies.  Furthermore,  −O2  can  be  converted 
spontaneously by superoxide dismutase (SOD) into H2O2 [33]. 
Figure 1. Atherosclerotic plaque formation process. LDLs at a high concentration inhibit endothelial
cells’ (EC) endocytosis capacity, migrate and accumulate in the intima. LDLs get oxidized and induce
VCAM (green square) expression in EC. Monocytes are recruited into the intima by VCAM interaction.
Monocytes transform into macrophages, which take-up oxLDLs, forming foam cells. Macrophages and
EC secrete chemokines a d recruit T-cells. T-cells p duce TNF-alph and IFN-gamma, amplifying
inflammation. Fibroblast growth factor (FGF) and platelet-derive growth factor (PDGF) stimulate
smooth-muscl cells (SMC) migration and proliferation. SMCs can also accumulate lipids, migrate
and proliferate. A lipid core is generated with necrotic foam cells surrounded by SMCs and a collagen
fibrous cap, resulting in thrombus formation.
3. ROS Types and Principal Sources in CVD
Among the ROS that have been associated with CVD induction or progression are −O2, H2O2,
OONO− and HO. −O2 and H2O2 are ROS produced enzymatically and have been shown to be involved
in physiological signaling and pathologies. Furthermore, −O2 can be converted spontaneously by
superoxide dismutase (SOD) into H2O2 [33].
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On the other hand, OONO− and HO are not considered ROS signaling molecules. These ROS
molecules are known to be highly reactive and contribute to oxidative stress and tissue damage.
HO is formed by H2O2 catalysis, and glutathione can scavenge it. −O2 and NO reaction produce
OONO−, which causes severe damage in endothelial tissue due to NO depletion and uncoupling of
the endothelium nitric oxide synthase (eNOS), leading to a cycled reaction that promotes dysfunction
progression in the endothelium [34].
The main sources of CVD-ROS are mitochondrial NADPH oxidases (NOX), xanthine oxidases
(XO), lypoxidases (LO) and myeloperoxidases (MPO). Furthermore, ROS-source-crosstalk has been
well documented, where H2O2 can activate NOX, as well as induce xanthine dehydrogenase
transformation into XO; OONO− induce −O2 production; and even more interesting, mitochondria
and NOX interact with each other, leading to an oxidative cycle [35]. A global overview of ROS and its
metabolic pathways is shown in Figure 2.
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3.1. Mitochondrial-ROS
Since 1961, ROS production has been shown to occur within mitochondria [36] linked to the
respiratory chain [37]. Mitochondria are nowadays considered as the major source of ROS in most
cells, particularly in cardiac cells [31]. The most abundant damaging ROS in vascular tissue is −O2,
and ROS-−O2 generation within mitochondria results mainly from the electron ransport chain (ETC)
pathway, although it has also been linked with H2O2 production [37]. Mitochondrial-ROS (mtROS)
is involved in several pathways and has a role in the innate immune response as a bactericidal
effector [38].
There is a close relation between mtROS and endothelial dysfunction, and an evident cross-talk
between mtROS and NOX-ROS has been demonstrated in several studies [39–43] where the production
of one m lecule leads to he induction of the other and vice versa. This mechanism is directly associated
with endothelial dysfunction through the influence of mtROS and −O2 production stimulation in
endothelial cells (EC). In this tissue, NO is considered fundamental to maintain its normal functionality;
however, in the presence of −O2, NO concentration is decreased, and the reaction between those two
molecules produces the extremely reactive species OONO− that can generate irreversible cellular
damage. A damaging cycle also takes place here, leading, due to the oxidation of the endothelial nitric
oxide synthase (eNOS) cofactor BH4 by OONO−, to eNOS uncoupling, and instead of producing NO,
induce an increase in −O2 production [32,44]. Other studies have also confirmed eNOS uncoupling
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consequences through inactivating phosphorylation, thereby demonstrating the association between
ROS sources, functionality and production [45–47].
The location of NOX4 in the outer mitochondrial membrane is another factor of interest in
mitochondrial crosstalk and NOX-ROS production. NOX4-ROS has been reported to be involved in the
activation of mitochondrial ROS generation by inner mitochondrial channels, such as ATP-sensitive
potassium channels (KATP), as well as the permeability transcription pore (mPTP), from which mtROS
can be transported out of the mitochondria to the cytosol, thereby maintaining NOX4-ROS production
and the cross-talk cycle [40]. Moreover, studies of disorders, such as diabetes, hypertension and aging
have shown an association between NOXs and mitochondria [48,49].
Several studies have shown that mitochondria and NOX both predominate as major ROS sources
in diabetes and that hyperglycemia is associated with mitochondria-NOX ROS crosstalk [50]. Type 2
diabetes has a causal link with CVD, and several studies of insulin secretagogues, such as sulfonylureas
in CVD, have shown a link to KATP channels. Their opening inhibition, as well as over-induction
lead to vascular complications and even to sudden cardiac death. In a diabetic state, a predominantly
decreased function of KATP channels has been observed, and it is suggested that, due to inhibited
ischemic preconditioning, myocardial infarction can happen. This can lead to a dramatic change of the
KATP channels status, which might abruptly induce its opening [51]. This event suggests a regulation
of mitochondrial-NOX interaction [32].
Within mitochondria, two sources of ROS production predominate in the ETC, complex I (CI)
and complex III (CIII), which can stimulate the opening of pores (mPTP and KATP) located in the
inner and outer mitochondrial membrane (IMM and OMM) [34]. A recent study determined that
CIII-ROS has cardio-protective functions, while CI-ROS production results in damage and association
with CVD [52]. mPTP opening was found to be correlated with incremental ROS production. ROS
generated from complex III delays channel opening, and its presence has been related with functional
recovery improvement after ischemic reperfusion (I/R) injury from which insult has been characterized
as a potent risk factor of oxidative stress. CI-ROS is not considered as a dominant source of ROS
under normal or healthy conditions, but it has been shown to be the major mitochondrial source
of electron leakage in I/R hearts [53]. Previous studies have also associated mPTP opening and
cardio-protective effects in I/R injuries from mitochondrial systems involved in ROS production with
deleterious consequences. mPTP inhibition by different molecules, such as cyclosporine A (CsA) and
inorganic phosphate, confer protection [54,55]. Furthermore, inhibition of other mitochondrial systems
that are involved in the production of ROS, such as monoamine oxidase (MAO) or p66Shc, have been
associated with protection against I/R injury, heart failure and vascular injury [56–59]. Although many
studies have shown new insights into the role of mt-ROS in CVD, there is still a substantial lack of
knowledge of the detailed mechanisms involved in mt-ROS production, as well as the mode of action
of the complexes.
3.2. NADPH Oxidases
NOX family enzymes are also known to be major contributors of ROS production. NOX1, NOX2,
NOX4 and NOX5 are complexes that assemble in the membrane and are expressed in vascular tissue
with the apparent only purpose of producing ROS. NOX2 and NOX4 have been reported to produce
ROS in cardiomyocytes and fibroblasts and NOX1, NOX4 and NOX5 in the vascular smooth-muscle
cells (VSMCs). NOX enzymes are characterized by −O2 production, but NOX4 is the exception to
the rule due to its predominant H2O2 generation. NOX-ROS molecules are involved in physiological
signaling, antimicrobial and inflammation host defence pathways and cellular differentiation [60,61].
NOX4 is known to be involved in VSMCs, stem cells, fibroblasts and cardiac cell migration and
differentiation [62], and a link between NOX4-ROS and the regulation of cellular phenotype was
reported [63]. NOX4 has been shown to increase ROS production while induced by transforming
growth factor-β (TGF-β) (Figure 3). Once NOX4 is expressed, it regulates smooth-muscle α-actin
(SMA), by oxidating the MKP-1phosphatase that can inactivate p38MAPK. ROS can also activate RhoA,
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which is a kinase that regulates the release of myocardin-related transcription factor (MRTF) and the
activation of the serum response factor (SRF), leading to SMA activation. Therefore, when NOX4-ROS
inhibits MKP-1, p38MAPK phosphorylates SRF, which binds to MRTF, and activates SMA, inducing
VSMCs differentiation. NOX4 function is associated with vascular injury. However it is known to
respond in later stages, counting as a susceptibility factor for advanced injury [64]. Although many
pathological events have been associated with an increased function of NOX4, it has a protective role
in hypertension disorders [65]. NOX4 overexpression has been shown to reduce basal blood pressure,
which is linked to H2O2 production.
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Figure 3. NADPH oxidase-modulated pathway in vascular smooth muscle cell differentiation.
The TGF-β-mediated inductio of NOX4 causes an inhibition of MKP-1 and activation of RhoA by ROS.
Under physiological conditions, MKP-1 i hibits p38MAPK, thereby preventing the RhoA-mediated
release and association of transcription elements SRF, which can be activated by p38MAPK, and MRTF,
which drive SMA gene expression.
A recent study has established the dual role of NOX-ROS [66]. This work showed that H2O2
generated through NOX disrupts tyrosine phosphorylation signaling by thiol oxidation of p-Tyrosine,
leading to its conversion to DOPA protein. DOPA protein can promote the disruption of networks and
therefore can lead to an alteration of biological processes. As such, in the presence of bacteria, H2O2
interferes with bacterial tyrosine kinase signaling by decreasing its virulent damage (Figure 4).
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Figure 4. Illustration of neutrophil NOX-HOCl production. Neutrophils have phagosomes and
granules in its cytoplasm. Granules contain myeloperoxidase (MPO) (orange). The NOX2 complex
(blue) gets assembled once the neutrophils initiate bacterial endocytosis. NOX2 produces H2O2 by
dismutation, and MPO reacts with H2O2 and chloride ions, thereby generating HOCl and water,
leading to neutrophil bactericidal effects.
J. Clin. Med. 2017, 6, 22 7 of 22
However, thiol-oxidation is a considerable pathway modifier event. When a protein undergoes
DOPA modification under oxidative stress or increased generation of H2O2, it can disrupt biological
processes and lead to disease. H2O2 production has also been linked to MPO, which are also
ROS-producing enzymes. Neutrophil-NOX production has been identified as a powerful bactericidal
through molecular oxygen reduction to −O2, its dismutation to H2O2, culminating with chloride
ions in the generation of hypochlorous acid (HOCL). HOCL even at low concentration is considered
as extremely reactive, inducing irreversible oxidation modification of methionine, and through this
mechanism, it is considered an efficient bacterial killer system. In conjunction with high NOX-H2O2
production, it can alter entire systems through degradation or misfolding of proteins [67–71]. H2O2 is
also associated with the activation of the p66SHC protein, which is involved in apoptosis and ROS
metabolism. H2O2 influences the p66SHC serine phosphorylation state and therefore its internalization
and accumulation in mitochondria. p66SHC binds to cytochrome C and promotes H2O2 generation and
therefore apoptosis [72]. Another noteworthy aspect is that NOX1 and NOX2 function in a molecular
complex and therefore depend on activators, regulators and binding proteins (p22Phox, NoxO1, NoxA1,
Rac1/2 for NOX1 and p22Phox, p47Phox, p67Phox, p40Phox and Rac1/2). NOX5 is dependent on calcium
and therefore regulated by calcium stimuli, which adds a considerable amount of complexity in its
role in CVD. On the other hand, NOX4 remains constitutively active in the presence of O2 within the
cell, depending on other proteins not for its activation, but for stability and localization. NOX4 is also
located within the mitochondria, specifically in the OMM, which demonstrates its role as a major ROS
source [73–75].
Upregulation or disturbance of NOX enzymes has been studied and shown to be associated
with endothelial dysfunction, atherosclerotic plaque formation, LDL oxidation, macrophages and
neutrophil recruitment, an increment in the pro-inflammatory molecules’ expression, senescence and
apoptosis in vascular tissue, contributing to CVD genesis and progression [76–78].
Risk factors, such as UV radiation, smoking, high calorie diets, diabetes, hypoxia, and endogenous
factors, such as pro-inflammatory molecules, growth factors, platelet-derived growth factor (PDGF),
and hormones, such as Ang II [76], insulin [77], can trigger NOX production. Since all of the NOX-ROS
trigger factors are associated with endothelial dysfunction, it can easily interact with other ROS sources
and these with each other, producing a ‘never ending’ oxidative stress state [78,79].
Cardiovascular dysfunction, as well as atherosclerosis has been related with an increased
expression of NOX2, NOX4 and NOX5, but only at early stages [80–82]. However, NOXs functionality
was shown to differ between age groups. NOX1/2 are mostly influential in young mice, and inhibition
by the deletion of p47phox in ApoE−/− mice reduced ROS levels and attenuated the development
of atherosclerosis [83–85]. A recent report showed that aged ApoE−/− and ApoE−/− /p47phox−/−
mice that developed atherosclerosis and vascular dysfunction were characterized by mitochondrial
dysfunction related with an upregulated expression of NOX4 in VSMCs [86]. To add to the general
complexity, diabetes has also been closely linked with CVD and NOX activity. NOX1 is activated by
a diabetic state, where hyperglycemia induces AngII and PDGF production that leads to vascular
dysfunction and NOX1-ROS production, hypertension and atherosclerosis [87]. Moreover, high glucose
has been reported to increase cardiomyocyte NOX4 production, which leads to cardiac damage [88].
Other CVD phenotypes, such as pulmonary artery hypertension (PAH) and atrial fibrillation (AF),
have been related with NOX activity. An upregulation of NOX2 and NOX4 is found in PAH, and their
inhibition was demonstrated to reverse PAH in animal models [89,90]. Atrial fibrillation (AT) has been
associated with an excess of ROS and a decrement of NO in myocardial tissue, and NOXs-ROS are
suggested to be involved in the induction phase of AF development [91]. This study also showed that
mitochondria and uncoupled ROS generation by eNOS influence long-term damage in AF.
3.3. Xanthine Oxidase
Hyperuricemia, defined as measurable elevated levels of uric acid (UA), is a common factor
observed in CVD patients. The involvement of UA in CVD pathophysiology has still to be elucidated,
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though xanthine oxidoreductase, the enzyme responsible for UA production, was suggested to play an
important role in CVD genesis. Xanthine dehydrogenase (XDH) and xanthine oxidase (XO) reduce
hypoxanthine and xanthine to UA. However, XDH uses NAD+ as an electron receptor and, when
triggered by factors, such as hypoxia, cell apoptosis, inflammation or ROS generation from other
sources (such as mitochondria or NOX) is converted to XO, whereby oxygen is used as an acceptor of
electrons, which results in the generation of −O2 and H2O2 [92]. XO was the first biological mechanism
to be identified as a producer of ROS [93] and, apart from its pathological function, has been identified
physiologically as a biological system that confers protection from pathogen infections. However,
XO-ROS production has been linked to endothelial dysfunction mainly due to the reaction of −O2
and NO that produces the OONO− reactive oxygen radical responsible for cellular damage [94].
Additionally, an excess of UA in certain CVD states, such as congestive heart failure (CHF) and CAD,
can function as a marker of upregulated XO activity, and inhibition through allopurinol therapy only
showed an improvement in patients with this characteristic [95–98].
A modulated XO activity has also been related with pulmonary hypertension [99], and the
signaling pathway of the transcription factor early growth response-1 (Egr-1) has targets implicated
in proliferation, inflammation and fibrosis; and it is known to be involved in pulmonary vascular
remodelling that leads to pulmonary hypertension [100]. Egr-1 itself was shown to be inducible by
XO-ROS through a chain of events initiated by ROS, whereby ROS interacts with the VSMCs-EGFR
membrane receptor, leading to MAPK/ERK1/2 phosphorylation, Egr-1 downstream activation and
ultimately to vascular remodelling and CVD [101,102].
3.4. Lipoxygenase
Among the lipoxygenases (LO), 5-LO and 12/15-LO have been shown to display a high correlation
with CVD genesis. Atherosclerosis, as well as I/R injury and therefore myocardial infarction have been
studied as a function of LO activity, and a tight association between LO enzymatic action, metabolites
and the development of CVD itself has been noticed.
Arachidonic acid (AA) is the LO substrate involved in its pathogenic role. AA is oxidized by LO,
resulting in hydroperoxides, which are further reduced into hydroxides and leukotrienes. Each LO
generates different metabolites according to the carbons in AA in which they act [103]. LOs mediate
AngII-induction of NOX in VSMCs, and AA catalysis generates ROS in vascular cells. 5-LO can be
upregulated by cytotoxicity and oxidative stress (NOX or mitochondrial ROS), and 5-LO catalysis of
AA generates 5-HETE and a leukotriene (LTA4), both of which are lipid mediators [104]. Metabolism
of LTA4 by several enzymes produces pro-inflammatory molecules (LTB4, LTC4, LTD4, LTE4) that
further interact, communicate and activate cells, such as endothelial cells, macrophages, neutrophils,
mast cells, foam cells and T-cells, that subsequently release cytokines and metalloproteinases with
pro-atherosclerotic function [105–109]. The involvement of 5-LO in CVD pathogenesis has been
postulated due to this modulation of inflammatory cells to increasing chemotaxis, inflammation,
permeability and injury by LTA4 [110]. Inhibition of 5-LO was shown to have a beneficial effect in
myocardial infarction and ischemia [111], but inhibition of 5-LO products (LTs-LTB4) did not result
in a similar improved outcome [112]. It has been highlighted that a much better understanding and
dissection of the activity and function of each of the components in the 5-LO pathway is needed in
order to develop an effective therapeutic method targeting these molecules [112].
12/15-LO activity is also involved in increased inflammation and oxidative stress and plays an
important role in atherosclerosis development [113]. AA metabolites 12-HPETE and 15-HPETE and
their reduced HETE forms generated by 12/15-LO are also pro-inflammatory and anti-inflammatory
molecules [114], and 12/15-LO overexpression has been associated with a high production of
pro-inflammatory cytokines, IL-6 and TNF-alpha [115]. 12/15-LO activity is characterized by
oxygenation of LDL molecules [116]. It was also shown that 12/15-LO activity associated with
NOX-ROS production plays an important part in oxidative stress in diabetic cardiomyopathy [117].
12/15-LO displays an increased activity in the diabetic heart. 12/15-LO inhibition has shown a
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decrement in an oxidative stress marker (4-HNE) in conjunction with ROS generation, and in turn,
NOX4 is associated with 12/15-LO activity in diabetic hearts [117]. Since diabetes has been associated
with several conditions, such as increased oxidative stress and hypertension, it is conceivable that
CVD can be also associated.
Recently, an association between ROS and 15-LO upregulation in pulmonary hypertension
(PH) was described in the literature, whereby damage in the pulmonary artery occurs by inducing
proliferation, leading to apoptosis [117]. AA-15-LO metabolites (15-HETE) enhance mitochondrial
ETC and NOX4-ROS generation and, under hypoxia, further induce endothelial cell migration and
pulmonary arterial smooth-muscle cell proliferation by p38 MAPK activation, leading to pulmonary
vascular remodelling.
3.5. Myeloperoxidase
Endothelial dysfunction is known to be under the influence of myeloperoxidase (MPO) activity,
and its excessive activity can lead to CVD, such as CAD [118,119]. MPO are present in high quantities
in neutrophils and to a lower extent in monocytes. When released, MPOs mediate H2O2 and halide or
semihalide ions reaction events that result in the production of hypohalous acids, such as hypochlorous
acid (HOCL−) and hypothiocyanous acid (HOSCN). These outcomes, generated by MPOs’ activity
are believed to have a bactericidal effect. However, when its activity is disturbed or upregulated, a
damaging outcome is expected [120]. Several pathologies have been associated with this functional
disturbance. HOCL− reacts mainly with nitrogen and sulphur atoms in cysteine residues present
in glutathione (GSH). Cys oxidation can inactivate or activate cellular molecules with important
roles, such as an inactivation of enzymes by modifying active-site Cys residues or an activation of
metalloproteases, such as MMP-7, which leads to a disturbance of the cellular redox balanced state and
can initiate atherogenesis [121]. Glutathione sulphonamide is the result of GSH oxidation primarily by
HOCL-, which makes it a potential marker for MPO damaged activity [122]. Smoking produces high
levels of SCN- and through its reaction with H2O2 by MPO leads to significantly increased quantities
of hypothyocianous acid (HOSCN) [123]. HOSCN is capable of reacting with thiols, resulting in
Trp oxidation, and this reaction mainly damages enzymes like tyrosine phosphatases, whereby cells
display hyperphosphorylation and altered MAPK signaling, which in turn can culminate in enhanced
apoptosis [124]. HOSCN is also able to modify LDL and HDL (oxLDL, oxHDL) [125–127] and oxidize
NO [128], and the product cyanate reacts with amides and generates a CVD predictor marker [129].
Diverse diseases, such as polycystic ovary syndrome (PCOS) and diabetes, have been related with
an increased risk in CVD genesis, and it can be associated with an involvement of inflammation and
oxidative stress in its pathogenesis. This is due to a leucocytes recruitment (insulin resistance (IR)),
increased ROS production, endothelial cell activation and release of adhesion molecules, leucocyte
binding and migration and elevated levels of cytokines [130–132]. Leucocyte activity is closely related
with this endothelial dysfunction, and it is suggested to have a heavy role in inflammation and CVD
risk, especially since MPO is a predominant oxidase within these cells. Recent studies have established
a link between the increment of MPO in leucocytes with IR and enhanced ROS production in PCOS
patients, thereby highlighting the influence of MPO in oxidative stress events [133,134]. Therefore,
MPO has been shown to be a main factor in inflammation and atherogenesis and is an underlying
factor of CVD genesis under certain conditions.
4. Common Pharmacological Approaches for CVD and Their Relationship with ROS
Current pharmacological approaches for CVD are focused on the use of statins, angiotensin
receptor blockers (ARBs) and antiplatelet agents. Although the main goal of these therapies is either
to lower blood pressure, regulate lipid content in the bloodstream and to prevent the formation of
atherosclerotic plaques, some of them have shown effects that are involved in the production or
scavenging of ROS.
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Statins are commonly used to treat CVD because of their lipid-lowering action. They do not
have a direct influence on ROS; instead, they have an indirect antioxidant effect that inhibits the
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase pathway. The inhibition of HMG
CoA perturbs the production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are
necessary for the generation of O2 from NOX. It also has been reported that the use of statins reduces
the incidence of CVD through antioxidant properties that enhance the expression of endothelial nitric
oxide synthase [135].
The relationship between angiotensin-converting enzyme (ACE) and its effect of increasing the
production of angiotensin II is another possible therapeutic option that could revert vascular damage.
It has been reported that high levels of angiotensin II contribute to the release of vascular O2 [136].
Alternatives have been proposed, and most of them are focused on the inhibition of ACE by using
receptor blockers, such as the angiotensin type I receptor blockers, which promote enhancement of
plasma levels of angiotensin II to stimulate angiotensin II type II receptors, leading to NO production
and vasodilation [137]. In the same way, the widespread use of calcium channel blockers for the
treatment of several CVDs due to their antioxidant and antihypertensive effects has also set an
opportunity to probe their possible effects over ROS-related pathways [138]. Several studies were
analysed in a meta-analysis in patients with CVD that were treated with calcium channel blockers,
and it was concluded that the risk of CVD was reduced with the use of calcium channel blockers when
compared to the traditional treatments [139].
It is evident that commonly-used therapies have become the first step towards the unveiling of
the relationship between drugs and ROS-mediated malignancies, such as CVD. There is still much to
confirm, and novel and more specific targeted therapies have appeared in recent years with a positive
promise of improving cardiovascular care.
5. ROS Biomarkers, Novel Therapies and Challenges
There are several novel potential biomarkers under investigation that can eventually unravel
CVD pathological mechanisms to help identify the onset and progression stages and ultimately reduce
CVD damage. Table 1 shows several cardiokines that have the potential to be CVD biomarkers [140].
Table 1. Cardiokines as potential CVD biomarkers.
Cardiokines Expression Status Condition
Atrial and B-Type
Natriuretic Peptides
Highly expressed In rats with pressure overload
Low level of expression In mice under fasting conditions
GDF-8 Highly expressed When skeletal muscle mass is increased
GDF-15 Highly expressed In patients with cardiac hypertrophy and chronic HF
CTRP9 Low level of expression In diabetic animals and humans. In subjects that havesuffered an acute myocardial infarction
Due to the prevalence of the disease across the global population and the projected incidence rate
to double between now and 2050, there is a critical need to develop new treatments that prevent or
inhibit CVD risk. It has become very apparent that oxidative stress is the major contributing factor in
CVD genesis, and therefore, new therapeutic approaches to combat its effects hold the potential to
ameliorate endothelial dysfunction and therefore prevent CVD development.
Caloric restriction (CR) has previously been shown to reduce −O2 generation, potentiating NO
bioavailability and therefore decreasing endothelial dysfunction [141]. It has been reported that
the activation of a member of the sirtuin family of protein deacetylases/deacylases (SIRT1) in old
mice by the compound SRT1720 can influence oxidative stress reduction, resulting in a reversal of
vascular dysfunction [142]. Furthermore, nicotinamide mononucleotide NMN supplementation is of
great interest, since it induces and enhances the activity of SIRT1 by increasing NAD+ bioavailability.
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NMN was shown to normalize superoxide production and to increase antioxidant MnSOD availability,
and it also ameliorates vascular changes that produce arterial stiffness. Interestingly, SIRT3, the
mitochondrial form of sirtuins, is known to directly influence MnSOD [143]. Although the exact
signaling pathways in which NMN plays a role have not been elucidated yet, its supplementation
outcome makes it suitable to be a potential novel therapeutic compound in combatting CVD [144].
Trehalose supplementation has also been studied for whether it can lead to an improvement
in microvascular dysfunction and CVD prevention on middle-aged and old adults. It has been
reported that trehalose supplementation improves resistance artery endothelium-dependent dilatation
(EDD) [145,146]. Since NO mediates this functional aspect, it was implied that trehalose increases NO
generation and availability within the cells. However, it was noted that a nutritional alteration had to
be factored in with this administration method due to the high caloric content of trehalose-needed
doses. It is clear that more research is needed in order for this compound to have a potential application
as a novel therapeutic drug [146].
Another example of a potential therapeutic agent is the antioxidant mitoquinone (MitoQ). It has
been previously reported that it reduces oxidative stress and increases glutathione peroxidase 1,
which is an antioxidant that converts peroxides into alcohol and water [147]. Subsequent research has
established the role of MitoQ, where it could be shown to be a modulator of leukocyte-endothelium
interaction [148]. MitoQ displayed a protective cardiovascular role by increasing leucocyte velocity and
decreasing its flux and adhesion to the endothelium, thus avoiding oxidative stress and inflammation.
Nucleic acid-based therapeutic delivery is also a promising strategy to fight CVD. Viral
vectors have been used as DNA-based therapeutics to target endothelial dysfunction. The Kuopio
Angiogenesis Trial 301 (KAT301) evaluated the efficacy of a mature form of vascular endothelial
growth factor (VEGF-D) using an adenoviral system delivery in CHD patients by NOGA®-mediated
transendocardial injection. In this study, an increment in myocardial perfusion was detected after
three months by VEGF-D influence [149,150]. Although viral vector delivery systems show a
promising improvement in endothelial dysfunction and DNA delivery, the possibility to interact
with pattern recognition receptors (PRRs) and potentiate endothelial dysfunction accounts for a greater
disadvantage. Alternatively, the development of nanotechnological platforms for drug delivery has
shown great promise in the treatment and improvement of endothelial dysfunction. An example of the
benefits of this system was reported by treating atherosclerotic mice with a nano-emulsion created with
omega-3-polyunsaturated fatty acid (PUFA)-rich oil-in-water that selectively delivered 17-B-estradiol
into targeted fibrin bulks within the plaque. This system improved NO production, decreased
pro-inflammatory molecules and reduced vascular injury, thereby ameliorating atherogenesis [151].
Several nanodelivery systems have been created, among them dendrimers (polymer-based DNA),
liposome-DNA complexes, lipid-polymer complexes and hydrogel-graphene oxide complexes.
The latter one was trialled by injecting it specifically into infected areas of the myocardium in rodents
and showed a decrease in MI injury after disease initiation [152]. Additionally, recent advances in
miRNA targeting have also gained attention in treating vascular disorders. Endothelial dysfunction
induces a number of genes associated with disease, which make them potential targets that could be
silenced by siRNAs. Viral complexes, as well as nanoparticle systems have successfully delivered
siRNAs, resulting in silenced molecules, such as CD40 (endothelial activation) and VCAM-1 (adhesion
molecule) and, thereby, leading to an improvement in CVD [153,154]. The latest addition in the
repertoire of therapeutic options is based on oligonucleotide-based therapies that include antisense
oligonucleotides (ASOs), anti-microRNA oligonucleotides (AMOs) and aptamers. ASOs selectively
block RNA translation. Currently, one FDA-approved ASO drug, mipomersen, targets apoB and is
used in the treatment of familial hypercholesterolemia. AMOs, however, are still in the exploratory
stage, and a recent study reported an increment of high-density lipoprotein HDL by the modulation of
the ABCA1 gene with miR-33a and miR-33b. Both ASOs and AMOs need further improvements in
order to increase their functions and to be more sensitive and specific [155,156]. Other technologies
that could show a beneficial therapeutic effect are aptamers, including DNA, RNA or peptide aptamers.
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Specific aptamers that target pro-inflammatory molecules and the von Willebrand factor, which are
associated with endothelial dysfunction, have been created and are undergoing clinical trials [157].
Another potential option is the development of new drugs based on an improvement of natural
compounds (phytochemicals) that have been considerably documented to have a positive effect in CVD.
Phytochemicals were attributed to attenuate CVD’s main mechanisms of inflammation and oxidative
stress. Phytochemicals from fruits (polyphenols: anthocyanins, ellagitannins, catechins, tannins),
vegetables (flavonoids: quercetin, lycopene), spices (piperine, safranal) and other sources (polyphenols:
catechins, epicatechin, 3-gallate, epic-gallocatechin) have been shown to have cardioprotective effects
and to reduce CVD factors [158–163].
It is well known that nutrients are crucial drivers of the cellular performance in our bodies.
As such, it is not surprising that there is a remarkable interest in the relation between dietary habits
and an association with oxidative stress. Even though the exact mechanisms and pathways in which
antioxidant nutrients could be involved have not been fully elucidated yet, a link between fruit,
vegetables, nuts and dietary patterns has been commonly reported.
Vitamin precursors, such as carotenes, vitamins A, E and C, as well as selenium, zinc, magnesium
and resveratrol, are known to have antioxidant properties and can provide protection against oxidative
damage and control of the glucose balance [164,165]. Nutritional studies with specific nuts, such as
pistachios and almonds, have shown a reduced lipid peroxidation and a protective effect against
oxidative stress in subjects with diabetes and metabolic syndrome [166,167].
Several studies have shown that, although some of these antioxidant nutrients can decrease
oxidative stress or ameliorate CVDs, unintended detrimental side-effects can occur [168]. Vitamin
C intake to reduce oxidative damage has also shown a molecular association with early-onset
of obesity [169], and resveratrol has been reported to induce oxidative breakage of DNA in
leukaemia [170]. Therefore, a simple nutritional supplementation needs to be carefully balanced
to avoid these unwanted secondary effects, but still maintain its prime purpose.
6. Conclusions
Though the influence of oxidative stress in CVD genesis has been clearly elucidated, the main
factor that remains is the deciphering of the precise mechanisms involved in CVD pathophysiology.
Despite this lack of information, several advances have been made regarding possible targets involved
in CVD pathogenesis, such as inflammation, oxidation, adhesion molecules, LDLs, endothelial tissue,
leucocytes and other factors. Their disturbance or alteration can potentially lead to endothelial
dysfunction, which is the main factor in CVD development. It has also become evident that numerous
interlinked cellular metabolic cascades form the basis of CVD and are intricately linked and modulated
by ROS (Figure 5).
Over the years, a number of discrepancies and inconsistencies were reported among the different
research studies, which to a great extent might be due to different approaches that were used to address
research questions, as well as the characteristics of the samples, such as type of subjects, conditions
or drug doses. This in turn calls for larger studies to be conducted to ascertain the effect of a specific
factor, a better understanding of the molecules involved in the precise stages of CVD development
and ultimately the description of more reliable biomarkers that can be targeted and potentially used in
the development of novel therapies.
Despite all of the remaining gaps and uncertainties in CVD genesis and development, as well as
the associated mechanisms affected by oxidative stress and its specific targets, research in this area is
constantly revealing new insights of CVD pathophysiology. Through the implementation of novel
integrative approaches, it might be possible to elucidate and decipher, in a concrete way, how the
biological systems within the body interact, where exactly damage occurs, where in the cell and at
which stage of the disease.
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Figure 5. Molecular pathways associated with CVD etiology. Contributing CVD factors, such as
diabetes, cause an imbalance of essential physiological pathways by impairing normal glycolysis (GL),
which feeds into the tricarboxylic acid pathway (TCA) that is directly linked to the electron transport
chain (ETC). Fatty acids, which can also contribute and feed into the TCA cycle through fatty acid
oxidation (FAO), are also implicated in CVD manifestation. Multiple enzymes involved in this scheme
have been shown to either modulate or directly generate ROS.
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